Literature DB >> 23210630

Pharmacological maintenance treatments of opiate addiction.

James Bell1.   

Abstract

For people seeking treatment, the course of heroin addiction tends to be chronic and relapsing, and longer duration of treatment is associated with better outcomes. Heroin addiction is strongly associated with deviant behaviour and crime, and the objectives in treating heroin addiction have been a blend of humane support, rehabilitation, public health intervention and crime control. Reduction in street heroin use is the foundation on which all these outcomes are based. The pharmacological basis of maintenance treatment of dependent individuals is to minimize withdrawal symptoms and attenuate the reinforcing effects of street heroin, leading to reduction or cessation of street heroin use. Opioid maintenance treatment can be moderately effective in suppressing heroin use, although deviations from evidence-based approaches, particularly the use of suboptimal doses, have meant that treatment as delivered in practice may have resulted in poorer outcomes than predicted by research. Methadone treatment has been 'programmatic', with a one-size-fits-all approach that in part reflects the perceived need to impose discipline on deviant individuals. However, differences in pharmacokinetics and in side-effects mean that many patients do not respond optimally to methadone. Injectable diamorphine (heroin) provides a more reinforcing medication for some 'nonresponders' and can be a valuable option in the rehabilitation of demoralized, socially excluded individuals. Buprenorphine, a partial agonist, is a less reinforcing medication with different side-effects and less risk of overdose. Not only is it a different medication, but also it can be used in a different paradigm of treatment, office-based opioid treatment, with less structure and offering greater patient autonomy.
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Keywords:  addiction; buprenorphine; diamorphine; heroin; methadone

Mesh:

Substances:

Year:  2014        PMID: 23210630      PMCID: PMC4014029          DOI: 10.1111/bcp.12051

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  59 in total

1.  Does retention matter? Treatment duration and improvement in drug use.

Authors:  Zhiwei Zhang; Peter D Friedmann; Dean R Gerstein
Journal:  Addiction       Date:  2003-05       Impact factor: 6.526

Review 2.  Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring.

Authors:  A Thomas McLellan; James R McKay; Robert Forman; John Cacciola; Jack Kemp
Journal:  Addiction       Date:  2005-04       Impact factor: 6.526

Review 3.  Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale.

Authors:  Sonja Brünen; Philippe D Vincent; Pierre Baumann; Christoph Hiemke; Ursula Havemann-Reinecke
Journal:  Ther Drug Monit       Date:  2011-10       Impact factor: 3.681

4.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

5.  Deaths of clients in methadone treatment in Texas: 1994-2002.

Authors:  Jane Carlisle Maxwell; Thomas W Pullum; Karen Tannert
Journal:  Drug Alcohol Depend       Date:  2004-12-07       Impact factor: 4.492

Review 6.  Efficacy of psychostimulant drugs for cocaine dependence.

Authors:  Xavier Castells; Miguel Casas; Clara Pérez-Mañá; Carlos Roncero; Xavier Vidal; Dolors Capellà
Journal:  Cochrane Database Syst Rev       Date:  2010-02-17

7.  Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients.

Authors:  Alexander K Elkader; Bruna Brands; Edward Dunn; Peter Selby; Beth Ann Sproule
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

8.  Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.

Authors:  Louisa Degenhardt; Briony K Larance; James R Bell; Adam R Winstock; Nicholas Lintzeris; Robert L Ali; Nicolas Scheuer; Richard P Mattick
Journal:  Med J Aust       Date:  2009-08-03       Impact factor: 7.738

Review 9.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

10.  Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials.

Authors:  Wim van den Brink; Vincent M Hendriks; Peter Blanken; Maarten W J Koeter; Barbara J van Zwieten; Jan M van Ree
Journal:  BMJ       Date:  2003-08-09
View more
  25 in total

1.  Themed section.

Authors:  M J Christie; M Connor; J R Traynor
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

Review 2.  Supervised dosing with a long-acting opioid medication in the management of opioid dependence.

Authors:  Rosella Saulle; Simona Vecchi; Linda Gowing
Journal:  Cochrane Database Syst Rev       Date:  2017-04-27

3.  Drugs for addiction: a therapeutic area in need of a 'shot in the arm'.

Authors:  Andrea L Malizia; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 4.  Supervised Injectable Opioid Treatment for the Management of Opioid Dependence.

Authors:  James Bell; Vendula Belackova; Nicholas Lintzeris
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 5.  Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder.

Authors:  Matthew L Banks
Journal:  Ann N Y Acad Sci       Date:  2016-12-09       Impact factor: 5.691

Review 6.  Insights from Preclinical Choice Models on Treating Drug Addiction.

Authors:  Matthew L Banks; S Stevens Negus
Journal:  Trends Pharmacol Sci       Date:  2016-12-02       Impact factor: 14.819

Review 7.  Neurobiologic Advances from the Brain Disease Model of Addiction.

Authors:  Nora D Volkow; George F Koob; A Thomas McLellan
Journal:  N Engl J Med       Date:  2016-01-28       Impact factor: 91.245

8.  Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure.

Authors:  Matthew L Banks; Blake A Hutsell; Bruce E Blough; Justin L Poklis; S Stevens Negus
Journal:  Int J Neuropsychopharmacol       Date:  2015-01-24       Impact factor: 5.176

Review 9.  Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.

Authors:  Francisco Navarrete; María Salud García-Gutiérrez; Ani Gasparyan; Amaya Austrich-Olivares; Jorge Manzanares
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

10.  The impact of dispensing fees on compliance with opioid substitution therapy: a mixed methods study.

Authors:  Alexandra Shepherd; Bianca Perrella; Hendrika Laetitia Hattingh
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.